Abstract
Endometriosis is the presence of endometrial tissue outside of the uterine cavity and is the most common gynecologic disorder in women of reproductive age. Although the quality of life for women with endometriosis is severely compromised, very little is known about the pathophysiology of endometriosis and current therapeutic strategies provide temporary symptomatic relief but not a cure. Endometriosis remains poorly understood primarily because of an inability to identify patients with early stage disease. Animal models have been developed to study early endometriosis but all have some problems that limit their usefulness in determination of the pathophysiology of endometriosis as it occurs in the human. We have preliminary evidence that in the presence of a three‐dimensional fibrin matrix, human endometrial glands, stroma, and neovascularization can develop in vitro, mimicking the earliest stages of endometriosis. We believe this model system reflects the situation in the peritoneal cavity of women following retrograde menstruation when endometrial fragments, fibrin, leucocytes and cytokines are trapped in pockets in the dependent parts of the pelvis, allowing endometrial cell proliferation, invasion and angiogenesis to occur. In the present review article, we will further discuss this in vitro model of early endometriosis and discuss possible anti‐angiogenic drugs that are already commercially available in an attempt to find an effective and specific treatment for endometriosis.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.